Key result
Percutaneous coronary intervention significantly decreased serum Angiopoietin-2 concentrations in patients with coronary heart disease from 4625.06 pg/ml to 3042.63 pg/ml.
Why the study?
Does percutaneous coronary intervention reduce serum Angiopoietin-2 concentrations in patients with coronary heart disease?
Observational (n=96)
No
Does percutaneous coronary intervention reduce serum Angiopoietin-2 concentrations in patients with coronary heart disease?
Answers are grounded in this paper and cite their sources.
PCI significantly decreases elevated serum Ang-2 concentrations in patients with CHD, suggesting Ang-2 may serve as a biomarker for myocardial ischemia and vessel remodeling.
BACKGROUND: Angiopoietin-2 (Ang-2) plays a crucial role in hypoxia-induced angiogenesis and is expressed only in sites of vascular remodeling. Ang-2 expression can be regulated by hypoxia inducible factors and other regulators with exposure to hypoxia. The objective of this study was to investigate the influence of percutaneous coronary intervention (PCI) on serum Ang-2 concentrations, and analyze the correlation between serum Ang-2 and the severity of coronary artery stenosis in patients with coronary heart disease (CHD). METHODS: Sixty-four patients with CHD were selected as the study group, each undergone PCI. Thirty-two healthy subjects were selected as the control group. Pre-PCI and post-PCI serum Ang-2 were measured by enzyme-linked immunosorbent assay. The severity of coronary artery stenosis was evaluated using angiographic Gensini scores, and the coronary collateral vessels were scored according to Rentrop's classification. RESULTS: Concentrations of pre-PCI serum Ang-2 in the study group were significantly higher than those in the control group (4625.06 ± 1838.06 vs. 1945.74 ± 1588.17 pg/ml, P < 0.01); however, concentrations of post-PCI serum Ang-2 were significantly lower than those of pre-PCI (3042.63 ± 1845.33 pg/ml vs. 4625.06 ± 1838.06 pg/ml, P < 0.01). Concentrations of pre-PCI serum Ang-2 were significantly correlated with Gensini scores (r = 0.488, P < 0.01); however, the decrease in serum Ang-2 after PCI was not correlated with Gensini scores, coronary collateral vessel grading, or left ventricular ejection fraction. CONCLUSIONS: Serum Ang-2 concentrations significantly increased in patients with CHD, and PCI treatment significantly decreased these concentrations. Serum Ang-2 concentrations, but not the decrease in serum Ang-2 concentrations, were significantly correlated with the severity of coronary artery stenosis. These results suggested that Ang-2 may be a biomarker of myocardial ischemia and vessel remodeling.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2016) conducted an observational in Coronary Heart Disease (n=96). Percutaneous coronary intervention (PCI) vs. Pre-PCI baseline was evaluated on Serum Angiopoietin-2 (Ang-2) concentrations (p=<0.01). Percutaneous coronary intervention significantly decreased serum Angiopoietin-2 concentrations in patients with coronary heart disease from 4625.06 pg/ml to 3042.63 pg/ml.
Synapse has enriched 10 related papers. Consider them for comparative context: